{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T11:41:09Z","timestamp":1742384469706,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T00:00:00Z","timestamp":1575590400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T00:00:00Z","timestamp":1575590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s40256-019-00388-8","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T03:02:40Z","timestamp":1575601360000},"page":"471-479","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Effectiveness and Safety of Restarting Oral Anticoagulation in Patients with Atrial Fibrillation after an Intracranial Hemorrhage: Analysis of Medicare Part D Claims Data from 2010\u20132016"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2833-6035","authenticated-orcid":false,"given":"Terri V.","family":"Newman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nemin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiqi","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir","family":"Saba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,6]]},"reference":[{"issue":"2","key":"388_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.15420\/usc.2016:1:1","volume":"10","author":"RB Fohtung","year":"2016","unstructured":"Fohtung RB, Rich MW. Identification of patients at risk of stroke from atrial fibrillation. US Cardiol Rev. 2016;10(2):60\u20134. https:\/\/doi.org\/10.15420\/usc.2016:1:1","journal-title":"US Cardiol Rev"},{"key":"388_CR2","unstructured":"Atrial Fibrillation Fact Sheet. CDC. 2017. Available at: https:\/\/www.cdc.gov\/dhdsp\/data_statistics\/fact_sheets\/fs_atrial_fibrillation.htm."},{"key":"388_CR3","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1161\/CIR.0000000000000040","volume":"130","author":"CT January","year":"2014","unstructured":"January CT, Wann LS, Alpert JS, et al. 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary. Circulation. 2014;130:2071\u2013104.","journal-title":"Circulation"},{"issue":"2","key":"388_CR4","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1161\/01.CIR.84.2.527","volume":"84","author":"DC Anderson","year":"1991","unstructured":"Anderson DC, Asinger RW, Newburg SM, et al. Stroke prevention in atrial fibrillation study. Final results. Circulation. 1991;84(2):527\u201339. https:\/\/doi.org\/10.1161\/01.CIR.84.2.527","journal-title":"Circulation"},{"issue":"5","key":"388_CR5","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1161\/STROKEAHA.113.000883","volume":"44","author":"E Albertsen Ida","year":"2013","unstructured":"Albertsen Ida E, Rasmussen Lars H, Overvad Thure F, Graungaard T, Larsen Torben B, Lip Gregory YH. Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin. Stroke. 2013;44(5):1329\u201336. https:\/\/doi.org\/10.1161\/STROKEAHA.113.000883.","journal-title":"Stroke"},{"key":"388_CR6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ijcha.2018.08.003","volume":"20","author":"T-Y Chang","year":"2018","unstructured":"Chang T-Y, Liao J-N, Chao T-F, Vicera JJ, Lin C-Y, Tuan T-C, et al. Oral anticoagulant use for stroke prevention in atrial fibrillation patients with difficult scenarios. Int J Cardiol Heart Vasc. 2018;20:56\u201362. https:\/\/doi.org\/10.1016\/j.ijcha.2018.08.003.","journal-title":"Int J Cardiol Heart Vasc."},{"key":"388_CR7","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1161\/STROKEAHA.113.004506","volume":"45","author":"GJ Hankey","year":"2014","unstructured":"Hankey GJ, Stevens SR, Piccini JP, et al. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke. 2014;45:1304\u201312.","journal-title":"Stroke"},{"key":"388_CR8","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.emc.2012.06.003","volume":"30","author":"JA Caceres","year":"2012","unstructured":"Caceres JA, Goldstein JN. Intracranial hemorrhage. Emerg Med Clin N Am. 2012;30:771\u201394.","journal-title":"Emerg Med Clin N Am"},{"key":"388_CR9","doi-asserted-by":"publisher","first-page":"e0166223","DOI":"10.1371\/journal.pone.0166223","volume":"11","author":"LB Schmidt","year":"2016","unstructured":"Schmidt LB, Goertz S, Wohlfahrt J, Melbye M, Munch TN. Recurrent intracerebral hemorrhage: associations with comorbidities and medicine with antithrombotic effects. PLoS ONE. 2016;11:e0166223\u2013e01662230166223.","journal-title":"PLoS ONE"},{"key":"388_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11883-018-0733-y","volume":"20","author":"Y-G Li","year":"2018","unstructured":"Li Y-G, Lip GYH. Anticoagulation resumption after intracerebral hemorrhage. Curr Atheroscler Rep. 2018;20:32.","journal-title":"Curr Atheroscler Rep."},{"key":"388_CR11","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1161\/CIRCULATIONAHA.115.015735","volume":"132","author":"PB Nielsen","year":"2015","unstructured":"Nielsen PB, Larsen TB, Skj\u00f8th F, Gorst-Rasmussen A, Rasmussen LH, Lip GYH. Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding. Circulation. 2015;132:517\u201325.","journal-title":"Circulation"},{"key":"388_CR12","doi-asserted-by":"crossref","first-page":"e000067","DOI":"10.1161\/JAHA.112.000067","volume":"2","author":"DE Singer","year":"2013","unstructured":"Singer DE, Hellkamp AS, Piccini JP, et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF Clinical Trial. J Am Heart Assoc. 2013;2:e000067.","journal-title":"J Am Heart Assoc."},{"key":"388_CR13","unstructured":"Chronic Conditions Data Warehouse [Online]. Available at: https:\/\/www.ccwdata.org\/web\/guest\/condition-categories."},{"key":"388_CR14","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093\u2013100.","journal-title":"Chest"},{"key":"388_CR15","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/ana.25079","volume":"82","author":"A Biffi","year":"2017","unstructured":"Biffi A, Kuramatsu JB, Leasure A, et al. Oral anticoagulation and functional outcome after intracerebral hemorrhage. Ann Neurol. 2017;82:755\u201365.","journal-title":"Ann Neurol"},{"key":"388_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1212\/CPJ.0000000000000425","volume":"8","author":"MA Hawkes","year":"2018","unstructured":"Hawkes MA, Rabinstein AA. Anticoagulation for atrial fibrillation after intracranial hemorrhage: a systematic review. Neurol Clin Pract. 2018;8:48\u201357.","journal-title":"Neurol Clin Pract."},{"key":"388_CR17","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1161\/STROKEAHA.116.016327","volume":"48","author":"SB Murthy","year":"2017","unstructured":"Murthy SB, Gupta A, Merkler AE, et al. Restarting anticoagulant therapy after intracranial hemorrhage: a systematic review and meta-analysis. Stroke. 2017;48:1594\u2013600.","journal-title":"Stroke"},{"key":"388_CR18","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1212\/WNL.0000000000004235","volume":"89","author":"E Korompoki","year":"2017","unstructured":"Korompoki E, Filippidis FT, Nielsen PB, et al. Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation. Neurology. 2017;89:687\u201396.","journal-title":"Neurology."},{"key":"388_CR19","doi-asserted-by":"publisher","first-page":"e019672","DOI":"10.1136\/bmjopen-2017-019672","volume":"8","author":"Z Zhou","year":"2018","unstructured":"Zhou Z, Yu J, Carcel C, et al. Resuming anticoagulants after anticoagulation-associated intracranial haemorrhage: systematic review and meta-analysis. BMJ Open. 2018;8:e019672.","journal-title":"BMJ Open."},{"key":"388_CR20","unstructured":"Hughes S. Resuming anticoagulants after ICH: a cautious nod? Medscape. 2019. Available at: https:\/\/www.medscape.com\/viewarticle\/879342."},{"key":"388_CR21","unstructured":"Neale T. Experts debate: is it \u2018nuts\u2019 to restart anticoagulation after lobar ICH? Cardiovascular Research Foundation. Available at: https:\/\/www.tctmd.com\/news\/experts-debate-it-nuts-restart-anticoagulation-after-lobar-ich."},{"key":"388_CR22","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1161\/STR.0000000000000069","volume":"46","author":"JC Hemphill","year":"2015","unstructured":"Hemphill JC, Greenberg Steven M, Anderson Craig S, et al. Guidelines for the management of spontaneous intracerebral hemorrhage. Stroke. 2015;46:2032\u201360.","journal-title":"Stroke"},{"key":"388_CR23","unstructured":"NOACs for stroke prevention in patients with atrial fibrillation and previous ICH (NASPAF-ICH). In: NIH U.S. National Library of Medicine: Clinical Trials. Accessed July 10, 2019. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02998905."},{"key":"388_CR24","unstructured":"Start or Stop Anticoagulants Randomised Trial (SoSTART). In: NIH U.S. National Library of Medicine: Clinical Trials. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03153150. Accessed 10 July 2019."},{"key":"388_CR25","unstructured":"Prevention of Stroke in Intracerebral Hemorrhage Survivors with Atrial Fibrillation (PRESTIGE-AF). In: NIH U.S. National Library of Medicine: Clinical Trials. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03996772. Accessed 10 July 2019."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-019-00388-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-019-00388-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-019-00388-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T20:49:25Z","timestamp":1665175765000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-019-00388-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,6]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["388"],"URL":"https:\/\/doi.org\/10.1007\/s40256-019-00388-8","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"type":"print","value":"1175-3277"},{"type":"electronic","value":"1179-187X"}],"subject":[],"published":{"date-parts":[[2019,12,6]]},"assertion":[{"value":"6 December 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The author(s) received no financial support for the research and publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Inmaculada Hernandez has received scientific advisory fees from Pfizer, outside of the submitted work. Dr. Samir Saba reports research support from Medtronic and Boston Scientific. Terri V. Newman, Nemin Chen, and Meiqi He have no disclosures to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}